XML 61 R48.htm IDEA: XBRL DOCUMENT v3.24.1
Note 8 - Commitments and Contingencies (Details Textual) - USD ($)
1 Months Ended 12 Months Ended
Oct. 30, 2023
Sep. 30, 2023
Mar. 31, 2023
Jun. 30, 2022
May 31, 2022
Dec. 31, 2023
Dec. 31, 2022
Operating Lease, Monthly Rent Payment   $ 4,700          
Operating Lease, Rent Expense, Annual Increase In Rent, Percent   2.00%          
Operating Lease, Weighted Average Remaining Lease Term (Year)           4 years 7 months 6 days  
Operating Lease, Weighted Average Discount Rate, Percent           9.60%  
Research and Development Expense           $ 19,487,000 $ 18,968,000
Stock Issued During Period, Value, New Issues           210,000  
Employee Agreements, Termination Benefits Provided To Key Employees, Aggregate Amount           5,500,000  
The 2023 Bank Guarantee [Member] | Line of Credit [Member] | Letter of Credit [Member]              
Line of Credit Facility, Maximum Borrowing Capacity           200,000  
Long-Term Line of Credit           0  
Houston Pharmaceuticals, Inc [Member]              
Costs and Expenses, Related Party           234,000 234,000
Houston Pharmaceuticals, Inc [Member] | Consulting Agreement on Licensed Molecules [Member]              
Other Commitment         $ 43,500    
Houston Pharmaceuticals, Inc [Member] | Agreement Providing Access to Laboratory Equipment [Member]              
Other Commitment         $ 15,000    
Other Commitments, Cancellation Period (Year)         60 years    
Olympia Drive W Bellfort LLC [Member]              
Operating Lease, Rent Expense, Annual Increase In Rent, Percent       3.00%      
Houston Pharmaceuticals, Inc [Member]              
Percentage of Rent Payable By Co-Lessee       50.00%      
Percentage Of Sub-lease Income Allocable To Co-lessee       50.00%      
Sublease Income           49,000 45,000
MD Anderson [Member]              
License Agreements Expense           258,000 264,000
Payments For Research And Development Agreement $ 800,000            
Research and Development Expense           775,000 $ 1,133,000
MD Anderson [Member] | Maximum [Member]              
License Agreement Annual License Fee           100,000  
MD Anderson [Member] | Maximum [Member] | Submission Of N D A And Receipt Of First Marketing Approval For Sale Of A Licensed Product [Member]              
Milestone Payment Liabilities           $ 600,000  
WPD Pharmaceuticals [Member] | License Termination [Member]              
Payments for Termination of Commitment     $ 700,000        
Stock Issued During Period, Value, New Issues     $ 800,000